ISSN: 1935-1232 (P)
Abstract
Clinical News
Author(s): Peter F. BuckleyOur field can be encouraged by several developments in the psychopharmacology of schizophrenia. We have previously described the initial clinical trials program of ITI-007. Results of two Phase 3 trials of ITI-007 have been reported as positive, with demonstrated antipsychotic efficacy and a favorable side effect profile (most prominently, mild sedation).